Under construction – not a live service

Skip to content

Frontlight Research

Institution

Samsung Medical Center

Seoul, South KoreaWebsite

Also known as: 삼성의료원 · SMC

743running trials
343closed trials
3researchers
45,532publications (OpenAlex)

Researchers

Running trials

Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Robotic Bronchoscopy for Small Lung Nodules Without a Bronchus Sign
NCT07862816· Intuitive Surgical· Source
Not yet recruiting
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
NCT07926321· Phase 2· Boehringer Ingelheim· Source
Not yet recruiting
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07852637· Phase 4· Samsung Medical Center· Source
Recruiting
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
NCT07884877· Phase 2· Samsung Medical Center· Source
Not yet recruiting
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840· Phase 3· Asan Medical Center· Source
Recruiting
Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC
NCT07933055· Phase 1/2· Txinno Bioscience Inc.· Source
Recruiting
A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy
NCT07911280· Phase 2· Samsung Medical Center· Source
Recruiting
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
NCT07776691· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Recruiting
Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD
NCT07770867· Neudive Inc.· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
NCT07594119· Phase 3· Rapport Therapeutics Inc.· Source
Recruiting
Wearable Eye Tracking During Bimanual Tasks in Children With Cerebral Palsy
NCT07806994· Samsung Medical Center· Source
Not yet recruiting
Effect of Mechanical Power-based Lung-protective Ventilation During One-lung Ventilation
NCT07772804· Samsung Medical Center· Source
Recruiting
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
NCT07493304· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Recruiting
Effect of Individualized Positive End-expiratory Pressure (PEEP) in Patients Who Have an Intrinsic PEEP During One-lung Ventilation
NCT07638176· Samsung Medical Center· Source
Not yet recruiting
Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation
NCT07486739· Seoul National University Hospital· Source
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT07586202· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
NCT07753200· Phase 4· Samsung Medical Center· Source
Recruiting
Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder
NCT07755605· Samsung Medical Center· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Recruiting
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
NCT07482865· Samsung Medical Center· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002· Phase 2/3· AbbVie· Source
Recruiting
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
NCT07367282· Phase 4· Junyeop Lee· Source
Recruiting
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07558915· Phase 1· Genentech, Inc.· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
NCT06995625· Phase 1· S&Ebio Co. Ltd.· Source
Recruiting
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
NCT07154745· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
NCT07486817· Phase 2· Boehringer Ingelheim· Source
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820· Phase 2· Elevar Therapeutics· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy
NCT07774520· Phase 2· Samsung Medical Center· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Takeda· Source
Recruiting
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832· Phase 1· AbbVie· Source
Recruiting
Empirical Anatomy-Based Ablation vs Emphasize Map-Guided Substrate Ablation in Persistent Atrial Fibrillation : (COMPASS-AF)
NCT07726901· Samsung Medical Center· Source
Recruiting
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
NCT07527858· Phase 2· Gilead Sciences· Source
Recruiting
PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer
NCT07607119· Samsung Medical Center· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376· Phase 3· Merck Sharp & Dohme LLC· Source
Not yet recruiting
Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
NCT07567508· Samsung Medical Center· Source

Showing 50 of 743.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer72 recruiting
Gastric and oesophageal cancer30 recruiting
Coronary artery disease27 recruiting
Colorectal cancer26 recruiting
Liver and biliary tract cancer25 recruiting
Ovarian cancer21 recruiting
Prostate cancer20 recruiting
Childhood cancers19 recruiting
Multiple myeloma18 recruiting
Pancreatic cancer18 recruiting
Metastatic breast cancer16 recruiting
Bladder cancer15 recruiting
Crohn's disease15 recruiting
Head and neck cancer14 recruiting
Heart failure14 recruiting
Triple-negative breast cancer12 recruiting
Endometrial cancer11 recruiting
Kidney cancer10 recruiting
Ulcerative colitis10 recruiting
Cervical cancer9 recruiting
High blood pressure9 recruiting
Acute myeloid leukaemia8 recruiting
Atrial fibrillation8 recruiting
Stroke8 recruiting
Chronic lymphocytic leukaemia7 recruiting
Pulmonary arterial hypertension7 recruiting
Acute lymphoblastic leukaemia6 recruiting
Alzheimer disease6 recruiting
Diffuse large B-cell lymphoma6 recruiting
Melanoma6 recruiting
Amyloidosis5 recruiting
Follicular lymphoma5 recruiting
Myelodysplastic syndromes4 recruiting
Neuroendocrine tumours4 recruiting
Sarcoma4 recruiting
Fatty liver disease (MASLD/MASH)3 recruiting
Idiopathic pulmonary fibrosis3 recruiting
Obesity3 recruiting
Autism2 recruiting
Depression2 recruiting
Epilepsy2 recruiting
IgA nephropathy2 recruiting
Immune thrombocytopenia (ITP)2 recruiting
Liver cirrhosis2 recruiting
Mantle cell lymphoma2 recruiting
Myeloproliferative neoplasms2 recruiting
Parkinson disease2 recruiting
Primary biliary cholangitis2 recruiting
Schizophrenia2 recruiting
Type 1 diabetes2 recruiting
Type 2 diabetes2 recruiting
Asthma1 recruiting
Bronchiectasis1 recruiting
Cerebral palsy1 recruiting
Charcot-Marie-Tooth disease1 recruiting
Duchenne muscular dystrophy1 recruiting
Essential tremor1 recruiting
Glioblastoma1 recruiting
Hepatitis B1 recruiting
Hodgkin lymphoma1 recruiting
Insomnia1 recruiting
Lupus (SLE)1 recruiting
Macular degeneration1 recruiting
Migraine1 recruiting
Myasthenia gravis1 recruiting
Myocarditis1 recruiting
Psoriasis1 recruiting
Psoriatic arthritis1 recruiting
Rheumatoid arthritis1 recruiting
Spinal muscular atrophy1 recruiting
Thyroid cancer1 recruiting

Closed trials

Withdrawn
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
NCT06886009· Boehringer Ingelheim· Source
Completed
Safety and Efficacy of Hip Assist Powered Exoskeleton for Gait Training in Patients With Late Subacute and Chronic Stroke
NCT07353203· Samsung Medical Center· Source
Terminated
Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma
NCT07043348· Seoul National University Hospital· Source
Completed
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
NCT07053345· Phase 4· Janssen Korea, Ltd., Korea· Source
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Effectiveness of Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom
NCT06769906· Samsung Medical Center· Source
Terminated
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
NCT06585488· Phase 1· BeOne Medicines· Source
Completed
Development of a Remote Therapy Protocol for Upper Limb Function Enhancement in Children With Cerebral Palsy
NCT06272760· Samsung Medical Center· Source
Completed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
NCT06523803· Phase 1· Zymeworks BC Inc.· Source
Terminated
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711· Phase 3· Mannkind Corporation· Source
Completed
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
NCT07343310· Phase 1· Kine Sciences Co., Ltd.· Source
Completed
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
NCT06568042· Phase 2· Eli Lilly and Company· Source
Completed
To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD
NCT06446193· Neudive Inc.· Source
Completed
Individualized Automatic Target Coaching Message for Glycemic Management and Depressive Symptom
NCT06525454· Samsung Medical Center· Source
Completed
A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
NCT06329141· Phase 2· Glaceum· Source
Completed
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403· Phase 3· Ipsen· Source
Completed
Factors Associated With Health-related Quality of Life in Patients With Breast Cancer-Related Lymphedema Undergoing Prospective Surveillance
NCT07165275· Samsung Medical Center· Source
Terminated
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
NCT06186076· Phase 1/2· Therapex Co., Ltd· Source
Completed
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
NCT06490328· Phase 3· Dongkook Pharmaceutical Co., Ltd.· Source
Completed
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
NCT06406439· G2e Co., Ltd· Source
Completed
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
NCT06287073· Boehringer Ingelheim· Source
Completed
A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
NCT06321523· Pfizer· Source
Completed
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879· Phase 2· Upstream Bio Inc.· Source
Completed
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
NCT06249919· Phase 1/2· Neuracle Science Co., LTD.· Source
Terminated
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
NCT06016270· Phase 1/2· STCube, Inc.· Source
Completed
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer
NCT06249854· Phase 2· Korea Institute of Oriental Medicine· Source
Completed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source
Completed
Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI
NCT06338956· Samsung Medical Center· Source
Completed
Switching to E-cigarette After PCI
NCT06338761· Samsung Medical Center· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629· Phase 3· Intellia Therapeutics· Source
Completed
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
NCT06122961· Novo Nordisk A/S· Source
Completed
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
NCT05784246· Phase 3· Eli Lilly and Company· Source
Completed
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
NCT06137742· Phase 1/2· Pfizer· Source
Completed
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT05867121· Phase 1· Genentech, Inc.· Source
Completed
Usability and Utility of Mindfulness-based Life Management Social Robots for Children and Adolescents in the Long-term Treatment
NCT06763042· Samsung Medical Center· Source
Terminated
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
NCT05998447· Phase 2· Genome & Company· Source
Completed
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source
Completed
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
NCT05665530· Phase 1· Prelude Therapeutics Incorporated· Source
Completed
A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
NCT06333964· Phase 3· Astrogen, Inc.· Source
Terminated
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
NCT05980416· Phase 1· Elevation Oncology· Source
Completed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT05909904· Phase 2· BeiGene· Source
Completed
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
NCT05907122· Phase 3· Amgen· Source
Completed
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691· Phase 2· Hoffmann-La Roche· Source
Completed
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480· Phase 2· Shionogi· Source
Completed
Effect of Lower Limb Constraint Induced Movement Therapy Using a Torque-Assisted Exoskeletal Wearable Device
NCT06830707· Samsung Medical Center· Source
Completed
The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.
NCT05947578· Phase 1· Cellatoz Therapeutics, Inc· Source
Completed
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
NCT05841030· Janssen Research & Development, LLC· Source

Showing 50 of 343.

Registry name variants (191)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Samsung Medical Center
Seoul, Seoul-teukbyeolsi [Seoul] 06351
832 trials
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi 06351
14 trials
Samsung Medical Center - PPDS
Seoul, 06351
14 trials
Samsung Medical Center
Gangnam-Gu, 6351
9 trials
Samsung Medical Centre
Seoul, 135-170
6 trials
Samsung Medical Center - Hematology & Oncology
Seoul, 06351
5 trials
Samsung Medical Center
Ganggu, 06351
4 trials
Samsung Medical Center_Seoul
Seoul, 06351
4 trials
Samsung Medical Center (Site 0082)
Seoul, 06351
4 trials
Samsung Medical Center (Site 1301)
Seoul, 06351
4 trials
Samsung Medical Center
Soeul, 06351
3 trials
- NCT07247175The Impact of Force Feedback in the dV5 Robotic Surgical System on Learning Curve and Safety in Robot-Assisted Radical Prostatectomy - A Prospective, Single-Center, Investigator-Initiated Clinical Trial
  Contact: Jiwoong Yu Clinical professor
- NCT06466135Study of WAL0921 in Patients With Glomerular Kidney Diseases
  Contact: Michelle Skupien
- NCT05501886Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Samsung Medical Center - Oncology Department
Seoul, 06351
3 trials
- NCT05614102A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
- NCT04423718Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
- NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Samsung Medical Center (Site 2303)
Seoul, 06351
3 trials
- NCT07776691A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
  Contact: Study Coordinator
- NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
  Contact: Study Coordinator
- NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
  Contact: Study Coordinator
Samsung Medical Center (Site 2801)
Seoul, 06351
3 trials
- NCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  Contact: Study Coordinator
- NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
- NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Samsung Medical Center_Cardiology
Seoul, 06351
2 trials
- NCT07567001A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  Contact: Novo Nordisk
- NCT05047263A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
Samsung Medical Center-Division of Hematology/Oncology (Site 3802)
Seoul, 06351
2 trials
- NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
  Contact: Study Coordinator
- NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Samsung Medical Center-Division of Hematology/Oncology (Site 3900)
Seoul, 06351
2 trials
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- NCT05319730A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
  Contact: Study Coordinator
Samsung Medical Center - Family Medicine
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp 06351
2 trials
- NCT06054555A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
- NCT05907122A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Samsung Medical Center (Site 1353)
Seoul, 06351
2 trials
- NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Samsung Medical Center (Site 1803)
Seoul, 06351
2 trials
- NCT04428151Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
- NCT03884101Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul
2 trials
- NCT06645678Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
  Contact: Youngil Koh, MD, PhD
- NCT04370496Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION)
  Contact: Yoo Young Lee, MD
Cardiac and Vascular Center; Samsung Medical Center
Seoul, 135-710
1 trial
- NCT05444452GENOSS Coronary Stent Clinical Trial
  Contact: Hyeon-Cheol Gwon, Professor
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, 135-710
1 trial
- NCT04909164The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients
Division of Gastroenterology, Department of Medicine, Samsung Medical Center
Seoul, 06351
1 trial
- NCT02914535Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Division of Hematology-Oncology Samsung Medical Center Seoul
Seoul
1 trial
- NCT05214183Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
Samsung Medical Center
Busan, 48775
1 trial
- NCT07527858Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Seoul, 06351
1 trial
- NCT07368088PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension
  Contact: Danbi Kim
Samsung Medical Center - Division of Hematology-Oncology
Seoul, 06351
1 trial
- NCT04742101Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine
Seoul, 06351
1 trial
- NCT01740427A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Samsung Medical Center-Division of Hematology/Oncology (Site 1004)
Seoul, 06351
1 trial
- NCT06312137A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  Contact: Study Coordinator
Samsung Medical Center-Division of Hematology/Oncology (Site 1102)
Seoul, 06351
1 trial
- NCT04895722Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Samsung Medical Center-Division of Hematology/Oncology (Site 1501)
Seoul, 06351
1 trial
- NCT06353386Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Samsung Medical Center-Division of Hematology/Oncology (Site 1804)
Seoul, 06351
1 trial
- NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Samsung Medical Center-Division of Hematology/Oncology (Site 1900)
Seoul, 06351
1 trial
- NCT05342636A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Samsung Medical Center-Division of Hematology/Oncology (Site 2351)
Seoul, 06351
1 trial
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Toll Free Number
Samsung Medical Center-Division of Hematology/Oncology (Site 2401)
Seoul, 06351
1 trial
- NCT04895358Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Samsung Medical Center-Division of Hematology/Oncology (Site 3101)
Seoul, 06351
1 trial
- NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  Contact: Study Coordinator
Samsung Medical Center-Division of Hematology/Oncology (Site 3502)
Seoul, 06351
1 trial
- NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Samsung Medical Center-Division of Hematology/Oncology (Site 5900)
Seoul, 06351
1 trial
- NCT06469944Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
  Contact: Study Coordinator
Samsung Medical Center-Division of Hematology/Oncology (Site 7900)
Seoul, 06351
1 trial
- NCT06445972Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
  Contact: Study Coordinator
Samsung Medical Center /ID# 125598
Seoul, 06351
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Samsung Medical Center /ID# 150433
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
Samsung Medical Center /ID# 153487
Seoul, 06351
1 trial
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Samsung Medical Center /ID# 153674
Seoul, 06351
1 trial
- NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Samsung Medical Center /ID# 158663
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
Samsung Medical Center /ID# 158692
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Samsung Medical Center /ID# 167564
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03345823A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
Samsung Medical Center /ID# 202710
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03539744A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Samsung Medical Center /ID# 213940
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04102020A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
Samsung Medical Center /ID# 217180
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04178317A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice
Samsung Medical Center /ID# 221068
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Samsung Medical Center /ID# 221091
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Samsung Medical Center /ID# 221224
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Samsung Medical Center /ID# 222906
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04189614An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Samsung Medical Center /ID# 223453
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Samsung Medical Center /ID# 225759
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Samsung Medical Center /ID# 226280
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04686136A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
Samsung Medical Center /ID# 227083
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Samsung Medical Center /ID# 228445
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Samsung Medical Center /ID# 230381
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03222609A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
Samsung Medical Center /ID# 231888
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Samsung Medical Center /ID# 234241
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04309474A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Samsung Medical Center /ID# 238919
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04433442Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
Samsung Medical Center /ID# 239009
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04826523Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
Samsung Medical Center /ID# 239895
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05206357Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Samsung Medical Center /ID# 240335
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03891446Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Samsung Medical Center /ID# 240882
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03844048An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Samsung Medical Center /ID# 242401
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05283720A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Samsung Medical Center /ID# 242408
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06508658A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Samsung Medical Center /ID# 245492
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06158841Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Samsung Medical Center /ID# 248936
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Samsung Medical Center /ID# 252023
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05782907Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Samsung Medical Center /ID# 253411
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Samsung Medical Center /ID# 255284
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05995353A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Samsung Medical Center /ID# 256941
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04928846A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Samsung Medical Center /ID# 257571
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Samsung Medical Center /ID# 258420
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Samsung Medical Center /ID# 258933
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Samsung Medical Center /ID# 259152
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04541810A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Samsung Medical Center /ID# 259254
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Samsung Medical Center /ID# 260008
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06191744Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Samsung Medical Center /ID# 260664
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT04777994Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
  Contact: Nicole Director Clinical Operations
Samsung Medical Center /ID# 262323
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06332534Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Samsung Medical Center /ID# 263294
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05512390A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Samsung Medical Center /ID# 265489
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Samsung Medical Center /ID# 265865
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Samsung Medical Center /ID# 266415
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05618028Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Samsung Medical Center /ID# 268720
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06614192A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Samsung Medical Center /ID# 269487
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Samsung Medical Center /ID# 270318
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06632951Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Samsung Medical Center /ID# 271591
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Samsung Medical Center /ID# 272640
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06603558Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
  Contact: Celine Im
Samsung Medical Center /ID# 272862
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07071519A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Samsung Medical Center /ID# 274440
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT06880744A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Samsung Medical Center /ID# 274452
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07023289A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Samsung Medical Center /ID# 275705
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07196644A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Samsung Medical Center /ID# 276261
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07059845A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Samsung Medical Center /ID# 276979
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07306832A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Samsung Medical Center /ID# 277600
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Samsung Medical Center /ID# 277615
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Samsung Medical Center /ID# 278083
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Samsung Medical Center /ID# 279397
Seoul, Seoul Teugbyeolsi 06351
1 trial
- NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Samsung Medical Center - Nephrology
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi] 6351
1 trial
- NCT04968184Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
Samsung Medical Center - Pediatric Neurology
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp 6351
1 trial
- NCT06180278Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Samsung Medical Center (Site 0010)
Seoul, 06351
1 trial
- NCT03179436Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Samsung Medical Center (Site 0063)
Seoul, 06351
1 trial
- NCT05017012A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Samsung Medical Center (Site 0071)
Seoul, 06351
1 trial
- NCT03062358Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
Samsung Medical Center (Site 0162)
Seoul, 06351
1 trial
- NCT06428409A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  Contact: Study Coordinator
Samsung Medical Center (Site 0172)
Seoul, 06351
1 trial
- NCT03834519Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Samsung Medical Center (Site 0193)
Seoul, 06351
1 trial
- NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Samsung Medical Center (Site 0200)
Seoul, 06351
1 trial
- NCT05406401A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Samsung Medical Center (Site 0202)
Seoul, 06351
1 trial
- NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  Contact: Study Coordinator
Samsung Medical Center (Site 0222)
Seoul, 06351
1 trial
- NCT03407144Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Samsung Medical Center (Site 0288)
Seoul, Kyonggi-do 06351
1 trial
- NCT04740307Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
Samsung Medical Center (Site 0300)
Seoul, 06351
1 trial
- NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
  Contact: Toll Free Number
Samsung Medical Center (Site 0301)
Seoul, 06351
1 trial
- NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Samsung Medical Center (Site 0311)
Seoul, 06351
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Samsung Medical Center (Site 0401)
Seoul, 06351
1 trial
- NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Samsung Medical Center (Site 0450)
Seoul, 06351
1 trial
- NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Samsung Medical Center (Site 0461)
Seoul, 06351
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Samsung Medical Center (Site 0502)
Seoul, 06351
1 trial
- NCT07221474A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
  Contact: Study Coordinator
Samsung Medical Center (Site 0551)
Seoul, 06351
1 trial
- NCT03820986Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
Samsung Medical Center (Site 0600)
Seoul, 06351
1 trial
- NCT05144841A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Samsung Medical Center (Site 0622)
Seoul, 06351
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Samsung Medical Center (Site 0651)
Seoul, 06351
1 trial
- NCT05064059A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Samsung Medical Center (Site 0704)
Seoul, 06351
1 trial
- NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Samsung Medical Center (Site 0792)
Seoul, 06351
1 trial
- NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  Contact: Study Coordinator
Samsung Medical Center (Site 0801)
Seoul, 06351
1 trial
- NCT07634471A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
  Contact: Study Coordinator
Samsung Medical Center (Site 0803)
Seoul, 06351
1 trial
- NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Samsung Medical Center (Site 0805)
Seoul, 06351
1 trial
- NCT03516981A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Samsung Medical Center (Site 0831)
Seoul, 06351
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Samsung Medical Center (Site 0926)
Seoul, 06351
1 trial
- NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  Contact: Study Coordinator
Samsung Medical Center (Site 0954)
Seoul, 06351
1 trial
- NCT04456699Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Samsung Medical Center - Site #100
Seoul, Seoul Teugbyeolsi 6351
1 trial
- NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Samsung Medical Center (Site 1001)
Seoul, Seoul-teukbyeolsi [Seoul] 06351
1 trial
- NCT03631784A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
Samsung Medical Center (Site 1064)
Seoul, 06351
1 trial
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Samsung Medical Center (Site 1100)
Seoul, 06351
1 trial
- NCT04924101Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Samsung Medical Center (Site 1104)
Seoul, 06355
1 trial
- NCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Samsung Medical Center (Site 1201)
Seoul, 06351
1 trial
- NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Samsung Medical Center (Site 1401)
Seoul, 06351
1 trial
- NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Contact: Study Coordinator
Samsung Medical Center (Site 1405)
Seoul, 06351
1 trial
- NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  Contact: Study Coordinator
Samsung Medical Center (Site 1601)
Seoul, 06351
1 trial
- NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Samsung Medical Center (Site 1604)
Seoul, 06351
1 trial
- NCT03635567Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Samsung Medical Center (Site 1700)
Seoul, 06351
1 trial
- NCT05508867A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Samsung Medical Center (Site 1801)
Seoul, 06351
1 trial
- NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Samsung Medical Center (Site 1807)
Seoul, 06351
1 trial
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
Samsung Medical Center (Site 1902)
Seoul, 06351
1 trial
- NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Samsung Medical Center (Site 2001)
Seoul, 06351
1 trial
- NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  Contact: Study Coordinator
Samsung Medical Center (Site 2103)
Seoul, 06351
1 trial
- NCT03036488Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Samsung Medical Center (Site 2200)
Seoul, 06351
1 trial
- NCT04728893Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
  Contact: Study Coordinator
Samsung Medical Center (Site 2304)
Seoul, 06351
1 trial
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
Samsung Medical Center (Site 2401)
Seoul, 06351
1 trial
- NCT03740165Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Samsung Medical Center (Site 2502)
Seoul, 06351
1 trial
- NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
  Contact: Study Coordinator
Samsung Medical Center (Site 2603)
Seoul, 06351
1 trial
- NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Samsung Medical Center (Site 2701)
Seoul, 06351
1 trial
- NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Samsung Medical Center (Site # 2703)
Seoul, 6351
1 trial
- NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
  Contact: Principal Investigator
Samsung Medical Center (Site 2900)
Seoul, 06351
1 trial
- NCT07405151A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
  Contact: Study Coordinator
Samsung Medical Center (Site 2902)
Seoul, 06351
1 trial
- NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
  Contact: Study Coordinator
Samsung Medical Center (Site 2903)
Seoul, 06351
1 trial
- NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
  Contact: Study Coordinator
Samsung Medical Center (Site 3001)
Seoul, 06351
1 trial
- NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Samsung Medical Center (Site 3101)
Seoul, 06351
1 trial
- NCT06428396Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Samsung Medical Center (Site 3104)
Seoul, 06351
1 trial
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
Samsung Medical Center (Site 3106)
Seoul, 06351
1 trial
- NCT07218029A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Samsung Medical Center (Site 3300)
Seoul, 06351
1 trial
- NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Samsung Medical Center (Site 3400)
Seoul, 06351
1 trial
- NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Samsung Medical Center (Site 3504)
Seoul, 06351
1 trial
- NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Samsung Medical Center (Site 3613)
Seoul, 06351
1 trial
- NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  Contact: Study Coordinator
Samsung Medical Center (Site 3801)
Seoul, 06351
1 trial
- NCT04626518Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Samsung Medical Center (Site 3807)
Seoul, 06351
1 trial
- NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Contact: Toll Free Number
Samsung Medical Center (Site 3811)
Seoul, 06351
1 trial
- NCT06305754Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Samsung Medical Center (Site 3902)
Seoul, 06351
1 trial
- NCT05845814A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Samsung Medical Center (Site 4064)
Seoul, 06351
1 trial
- NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Samsung Medical Center (Site 4100)
Seoul, 06351
1 trial
- NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Samsung Medical Center (Site 4200)
Seoul, 06351
1 trial
- NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Samsung Medical Center (Site 4201)
Seoul, 06351
1 trial
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Samsung Medical Center (Site 4902)
Seoul, 06351
1 trial
- NCT06483334A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Samsung Medical Center (Site 5005)
Seoul, 06351
1 trial
- NCT04949256Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Samsung Medical Center (Site 5101)
Seoul, 06351
1 trial
- NCT06780137A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
  Contact: Study Coordinator
Samsung Medical Center (Site 5203)
Seoul, 06351
1 trial
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
Samsung Medical Center (Site 5206)
Seoul, 06351
1 trial
- NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
  Contact: Study Coordinator
Samsung Medical Center (Site 5801)
Seoul, 06351
1 trial
- NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
  Contact: Study Coordinator
Samsung Medical Center (Site 5902)
Seoul, 06351
1 trial
- NCT07232602KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
  Contact: Study Coordinator
Samsung Medical Center (Site 9900)
Seoul, 06351
1 trial
- NCT06780111Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
  Contact: Study Coordinator
Samsung medical center (Site B)
Seoul, 06351
1 trial
- NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Samsung Medical Center (Site C)
Seoul, 06351
1 trial
- NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Samsung Medical Center (Site D)
Seoul, 06351
1 trial
- NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Samsung Medical Center,Substudy-01
Seoul, 06351
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Samsung Medical Center,Substudy-02
Seoul, 06351
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Samsung Medical Center,Substudy-03
Seoul, 06351
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Samsung Medical Centre (Site A)
Seoul, 06351
1 trial
- NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Seoul Samsung Medical Center
Seoul, 06351
1 trial
- NCT03840291Resolution of Thrombi in Left Atrial Appendage With Edoxaban

Conditions

Diseases this institution publishes on or runs trials for.

Lung cancer195 works · 196 trials
Liver and biliary tract cancer127 works · 66 trials
Gastric and oesophageal cancer98 works · 80 trials
Ovarian cancer38 works · 42 trials
Pancreatic cancer37 works · 36 trials
Bladder cancer37 works · 43 trials
Multiple myeloma34 works · 43 trials
Kidney cancer30 works · 33 trials
Triple-negative breast cancer28 works · 25 trials
Insomnia27 works · 2 trials
Metastatic breast cancer26 works · 53 trials
Crohn's disease24 works · 25 trials
COPD23 works · 5 trials
Obstructive sleep apnoea18 works · 0 trials
Endometrial cancer17 works · 24 trials
Diffuse large B-cell lymphoma16 works · 26 trials
Head and neck cancer11 works · 36 trials
Neuroendocrine tumours11 works · 7 trials
Hepatitis B11 works · 7 trials
Idiopathic pulmonary fibrosis11 works · 11 trials
Thyroid cancer10 works · 9 trials
Hypertrophic cardiomyopathy10 works · 0 trials
Cerebral palsy10 works · 3 trials
Myocarditis9 works · 1 trial
Charcot-Marie-Tooth disease8 works · 2 trials
Neuromyelitis optica (NMOSD)7 works · 1 trial
Frontotemporal dementia7 works · 1 trial
Multiple system atrophy6 works · 1 trial
Myasthenia gravis6 works · 3 trials
Liver cirrhosis6 works · 3 trials

Institution data: ROR 05a15z872 (CC0-1.0)Updated 12 Nov 2026

Report an error